Roche posts 7% rise in Q3 2023 group sales
Roche has posted a 7% rise in group sales to SFr14.27bn ($15.91bn) at constant exchange rates (CER) in the third quarter (Q3) of 2023, compared to SFr14.74bn ($16.44bn) in Q3 2022. The pharmaceuticals division of the company saw an 11% growth in sales to SFr10.94bn from Sfr10.84bn in the same quarter of the previous year. Confirming the company’s 2023 outlook as previously issued, Roche noted that the substantial drop in Covid-19 product sales impacted the reduced group sales. US sales of SFr5.93bn showed an 11% rise from Sfr5.83bn in Q3 2022. Vabysmo, Ocrevus and Hemlibra were the key drivers for the rise in sales. Sales stood at SFr2.15bn and SFr727bn in Europe and Japan, indicating a growth of 9% and 1% respectively compared with Q3 2022 For the international region, which comprises Asia Pacific, Latin America, the Middle East, Africa and Canada, along with Central Eastern Europe, Türkiye, Russia and the Indian subcontinent (CEETRIS), sales for the quarter were reported to be SFr2.12bn against SFr2.18bn in Q3 2022. Roche CEO Thomas Schinecker stated: “We achieved good results in the first nine months of 2023, more than compensating for the expected decline in demand for Covid-19 products. “Our group sales excluding Covid-19 products continued to grow strongly by plus 9% at constant exchange rates. “Additionally, we made significant progress in our product pipeline with numerous positive clinical studies.” Roche has also entered a strategic collaboration and licensing agreement with Monte Rosa Therapeutics to discover and develop molecular glue degraders for cancer and neurological ailments.
Roche has posted a 7% rise in group sales to SFr14.27bn ($15.91bn) at constant exchange rates (CER) in Q3 2023.
What's Your Reaction?
